Clinical Trial Update: Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates an autologous engineered skin substitute for partial- and full-thickness burn wounds. The current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burn Injuries

Drugs mentioned

• Autologous Engineered Skin Substitute

Snippet

Sponsor: Amarantus BioScience Holdings, Inc. | Conditions: Thermal Injury, Deep Partial-Thickness Burn | Phase 2 | Status: UNKNOWN